Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
embryonal
genomics
pleomorphic
rhabdomyosarcoma
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
12
03
2024
received:
28
01
2024
accepted:
08
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
ppublish
Résumé
Pleomorphic rhabdomyosarcoma (PRMS) is a rare and highly aggressive sarcoma, occurring mostly in the deep soft tissues of middle-aged adults and showing a variable degree of skeletal muscle differentiation. The diagnosis is challenging as pathologic features overlap with embryonal rhabdomyosarcoma (ERMS), malignant Triton tumor, and other pleomorphic sarcomas. As recurrent genetic alterations underlying PRMS have not been described to date, ancillary molecular diagnostic testing is not useful in subclassification. Herein, we perform genomic profiling of a well-characterized cohort of 14 PRMS, compared to a control group of 23 ERMS and other pleomorphic sarcomas (undifferentiated pleomorphic sarcoma and pleomorphic liposarcoma) using clinically validated DNA-targeted Next generation sequencing (NGS) panels (MSK-IMPACT). The PRMS cohort included eight males and six females, with a median age of 53 years (range 31-76 years). Despite similar tumor mutation burdens, the genomic landscape of PRMS, with a high frequency of TP53 (79%) and RB1 (43%) alterations, stood in stark contrast to ERMS, with 4% and 0%, respectively. CDKN2A deletions were more common in PRMS (43%), compared to ERMS (13%). In contrast, ERMS harbored somatic driver mutations in the RAS pathway and loss of function mutations in BCOR, which were absent in PRMS. Copy number variations in PRMS showed multiple chromosomal arm-level changes, most commonly gains of chr17p and chr22q and loss of chr6q. Notably, gain of chr8, commonly seen in ERMS (61%) was conspicuously absent in PRMS. The genomic profiles of other pleomorphic sarcomas were overall analogous to PRMS, showing shared alterations in TP53, RB1, and CDKN2A. Overall survival and progression-free survival of PRMS were significantly worse (p < 0.0005) than that of ERMS. Our findings revealed that the molecular landscape of PRMS aligns with other adult pleomorphic sarcomas and is distinct from that of ERMS. Thus, NGS assays may be applied in select challenging cases toward a refined classification. Finally, our data corroborate the inclusion of PRMS in the therapeutic bracket of pleomorphic sarcomas, given that their clinical outcomes are comparable.
Substances chimiques
Biomarkers, Tumor
0
Retinoblastoma Binding Proteins
0
RB1 protein, human
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23238Subventions
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Furlong MA, Mentzel T, Fanburg‐Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle‐specific markers. Mod Pathol. 2001;14(6):595‐603.
Stock N, Chibon F, Nguyen Binh MB, et al. Adult‐type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol. 2009;33(12):1850‐1859.
Noujaim J, Thway K, Jones RL, et al. Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study. Anticancer Res. 2015;35(11):6213‐6217.
Li G, Ogose A, Kawashima H, et al. Cytogenetic and real‐time quantitative reverse‐transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;192(1):1‐9.
Gordon A, McManus A, Anderson J, et al. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma‐associated PAX3‐FOXO1A fusion gene in one case. Cancer Genet Cytogenet. 2003;140(1):73‐77.
Knuutila S, Björkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998;152(5):1107‐1123.
Kommoss FKF, Stichel D, Mora J, et al. Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1‐associated subgroup. Mod Pathol. 2021;34(8):1558‐1569.
Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering‐integrated mutation profiling of actionable cancer targets (MSK‐IMPACT): a hybridization capture‐based next‐generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251‐264.
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847‐2849.
Haduong JH, Heske CM, Allen‐Rhoades W, et al. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022;69(4):e29511.
Bompas E, Campion L, Italiano A, et al. Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. Cancer Med. 2018;7(8):4023‐4035.
Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO‐EURACAN‐GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32(11):1348‐1365.
von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815‐833.
Stout AP. Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946;123(3):447‐471.
Enzinger FM. Malignant fibrous histiocytoma 20 years after stout. Am J Surg Pathol. 1986;10:43‐53.
Wesche WA, Fletcher CD, Dias P, Houghton PJ, Parham DM. Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcomas. Am J Surg Pathol. 1995;19(3):261‐269.
Cui S, Hano H, Harada T, Takai S, Masui F, Ushigome S. Evaluation of new monoclonal anti‐MyoD1 and anti‐myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol Int. 1999;49(1):62‐68.
Molenaar WM, Oosterhuis AM, Ramaekers FC. The rarity of rhabdomyosarcomas in the adult. A morphologic and immunohistochemical study. Pathol Res Pract. 1985;180(4):400‐404.
Miettinen M. Rhabdomyosarcoma in patients older than 40 years of age. Cancer. 1988;62(9):2060‐2065.
Schürch W, Bégin LR, Seemayer TA, et al. Pleomorphic soft tissue myogenic sarcomas of adulthood: a reappraisal in the mid‐1990s. Am J Surg Pathol. 1996;20(2):131‐147.
Gaffney EF, Dervan PA, Fletcher CD. Pleomorphic rhabdomyosarcoma in adulthood. Analysis of 11 cases with definition of diagnostic criteria. Am J Surg Pathol. 1993;17(6):601‐609.
Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the soft tissue sarcoma Committee of the Children's Oncology Group. Cancer. 2008;113(11):3242‐3247.
Furlong MA, Fanburg‐Smith JC. Pleomorphic rhabdomyosarcoma in children: four cases in the pediatric age group. Ann Diagn Pathol. 2001;5(4):199‐206.
Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, intergroup rhabdomyosarcoma studies I and II: clinicopathologic correlation. J Clin Oncol. 1988;6(1):67‐75.
Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res. 2011;170(2):e243‐e251.
Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76(6):1073‐1085.
Beird HC, Wu CC, Nakazawa M, et al. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv. 2023;4(4):100224.
Chelsky ZL, Paulson VA, Chen EY. Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targets. Genes Chromosomes Cancer. 2022;61(3):138‐147.
Pondrom M, Bougeard G, Karanian M, et al. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: the French experience. Pediatr Blood Cancer. 2020;67(9):e28486.
Trahair T, Andrews L, Cohn RJ. Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer. 2007;48(3):345‐348.
Hettmer S, Archer NM, Somers GR, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014;120(7):1068‐1075.
Shern JF, Selfe J, Izquierdo E, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium. J Clin Oncol. 2021;39(26):2859‐2871.
Taylor AC, Shu L, Danks MK, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000;35(2):96‐103.
Ognjanovic S, Martel G, Manivel C, Olivier M, Langer E, Hainaut P. Low prevalence of TP53 mutations and MDM2 amplifications in pediatric rhabdomyosarcoma. Sarcoma. 2012;2012:492086.
Shenoy A, Alvarez E, Chi YY, et al. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2021;143:127‐133.
Paulson V, Chandler G, Rakheja D, et al. High‐resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50(6):397‐408.
Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun. 2015;6:7557.
Malarikova D, Berkova A, Obr A, et al. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers. 2020;12(8):2120.
Busch C, Geisler J, Knappskog S, Lillehaug JR, Lønning PE. Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine. J Invest Dermatol. 2010;130(10):2514‐2516.
Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis. 2002;23(4):645‐655.
Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion‐positive and fusion‐negative tumors. Cancer Discov. 2014;4(2):216‐231.
Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18(3):748‐757.
Ciccarelli C, Vulcano F, Milazzo L, et al. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem‐like cell population. Mol Cancer. 2016;15:16.
Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL‐6 repression. Genes Dev. 2000;14(14):1810‐1823.
Grossmann V, Tiacci E, Holmes AB, et al. Whole‐exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118(23):6153‐6163.
Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329‐334.
Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype‐specific somatic mutations. Nature. 2012;488(7409):106‐110.
Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and Morphology. Genes Chrom Cancer. 1998;22(1):16‐25.
Goldstein M, Meller I, Issakov J, Orr‐Urtreger A. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia. 2006;8(5):332‐343.
Williamson D, Missiaglia E, de Reyniès A, et al. Fusion gene‐negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28(13):2151‐2158.
Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A. 1989;86(19):7480‐7484.
Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950‐965.e928.
Gounder MM, Agaram NP, Trabucco SE, et al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun. 2022;13(1):3406.